Treatment guidelines after an outbreak of azithromycin-resistant Neisseria gonorrhoeae in SA

The Lancet Infectious Diseases, 17 (2), February 2017

Abstract:

Antimicrobial resistance in Neisseria gonorrhoeae is recognised globally as a public health threat. Dual therapy with ceftriaxone and azithromycin has been introduced in Australia and elsewhere as the first-line treatment recommendation for gonorrhoea. While there have been only sporadic reports of ceftriaxone-resistant gonococci, globally there have been increasing reports of N gonorrhoeae resistance to azithromycin.¹ The Australian Gonococcal Surveillance Programme² is one of the most comprehensive N gonorrhoeae antimicrobial resistance surveillance programmes worldwide.

• Read more here